Summary In discussions on breast cancer screening, much attention has been focussed on the possible morbidity generated by screening. Favourable effects like the prevention of advanced disease seem underestimated, probably because quantification is that difficult. To analyse the amount of care and treatment given to women with advanced breast cancer, we report on patients followed from first recurrence until death using patient files and national sources. A random sample of 60 female cases from computerised registries of two cancer centres and a sample of 20 cases from a non-computerised hospital registry was taken. A total of 68 patient files were sufficiently documented. A woman with advanced breast cancer is estimated to have a 39% loss in utility compared to a healthy woman (range 27-45%). Hormonal treatment is the main modality during 14 and chemotherapy during 4 months. Total medical cost from diagnosis of advanced disease until death amounts to 17,100 US dollars, or 21,000 when including extramural cost.
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The effect of breast cancer screening by preventing the occurrence of advanced disease is quantified. The resulting gain in quality of life contributes 70% of the total gain in quality of life. In the long run, almost half of the annual cost of screening will be offset by savings in the cost for advanced disease. Only the changes in palliative surgery and/or radiotherapy will be small in contrast to primary treatment changes. Besides the mortality reduction, screening is justified by the improvements in quality of life and cost savings for women prevented from reaching advanced disease.
Population screening for breast cancer has been introduced in several countries. Trials have shown that it is possible to reduce breast cancer mortality by mammographic screening of women of 50 years and older (Wald et al., 1991) . The seemingly less favourable mortality reductions achieved in two trials (Andersson et al., 1988; Roberts et al., 1990 ) resulted in articles that emphasise possible disadvantages of breast cancer screening, and attention has been focussed on the morbidity generated (Roberts, 1989; Dixon & John, 1992) . However, the impact of screening on the prevention of advanced disease and its morbidity is generally neglected. In contrast to the research in costs and possible adverse effects of screening (Ellman et al., 1989) 1985-1989, (b) had received primary treatment with curative intent, (c) first diagnosis of breast cancer between the ages 50 and 80, were randomly taken. All 20 available female cases from the smaller hospital which met criteria (a) and (b) were used. All patients had developed distant metastases. A total of 68 patient files (see Table I (Bombardier et al., 1982) . Using this function, the utilities for the five different states were computed from the scores of the direct scaling method. The average loss in quality of life for female breast cancer patients with advanced disease was calculated by combining the utilities with the mean durations of the different disease episodes found in the 68 patients.
Calculations of costs have been restricted to direct medical cost and were based on the detailed data from the files. Only the exact number of out-patient visits, if patients did not receive chemotherapy, was estimated (Holli et al., 1989 (Tabar et al., 1989) and in Malm6 (Andersson et al., 1988 ) after 8-9 years for women in the study group aged 50-70 assuming a trial situation of 70% attendance and a 2-year interval. Effects are presented in this article for 2-yearly screening for women aged 50-70 (Dutch policy) and for 3-yearly for women aged 50-65 (Vessey, 1991) (attendance rate 70%). Cases of advanced disease that are prevented by screening are assumed to be a random subset of all cases of advanced disease. The overall impact of the screening programme, including unfavourable effects and favourable effects other than the prevention of advanced disease, have been taken into account but are described elsewhere in detail .
Results
Systemic and palliative treatment Hormonal treatment was the first-line treatment in 57% of all women with advanced disease and chemotherapy in only 16%. Most patients received more than one treatment modality during the period from recurrence till death. Out-patient drug treatment was the most frequently applied modality: 84% of women received hormonal treatment and 69% received chemotherapy during one or more time periods (Table  II) . Tamoxifen, aminoglutethimide, high dose progestins and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) were used most frequently. If Tamoxifen had been prescribed to a woman, she had taken it during 9.5 months on average. Aminoglutethimide, mostly used in the second or third line, and CMF were prescribed for respectively 6 and 5.5 months on average. In the lower part of the Figure 1 shows the survival curve from the month of first recurrence of all 68 women. The three patient groups from the separate centres show a striking resemblance. The mean post-recurrence survival is 19.7 months in hospital 1, 21.7 months in hospital 2 and 22.7 months in hospital 3 (not significantly different; log-rank test).
Quality of life
The experts' assessment on quality of life did not in general differ significantly from that of the other persons (health professionals), both in ranking order and in mean or median value . Only palliative hormonal treatment was considered to have less impact on quality of life by the clinicians than by the non-clinicians (Table III, (Table IV) . Radiation therapy (9%) was used frequently but mostly for a relatively short period (6.9 sessions per palliative radiation treatment). Diagnostic testing is also costly (10%); e.g. approximately one X-ray was made every month to follow the course of metastases or to find the source of complaints (Table II) . The other 19% are cost for out-hospital visits to specialists, cost of drugs and cost for nursing homes. Despite the fact that medication is the most frequently applied treatment modality in advanced disease, it is responsible for only 8% of the total cost. Impact of nationwide screening With ten 2-yearly invitations for screening to women between ages 50 and 70, total breast cancer mortality is expected to be reduced by 16% in the Dutch population. However, it takes considerable time before this reduction will be reached. Without a screening programme, the total number of women that will die from breast cancer will rise to approximately 4245 in the year 2014. Screening will lower this figure by 655 in that year. As nearly all women with breast cancer in an advanced stage will ultimately die from the disease, the number of new patients for treatment of advanced disease will decrease proportionally to the expected decrease in breast cancer mortality. Table V summarises the impact of nationwide screening in the Netherlands, especially concerning the prevention of advanced disease in the year 2014. The lower breast cancer mortality as a result of the Dutch screening policy reflects 6630 life-years gained in 2014. In addition (655 x 1.75 = ) 1150 women-years with the diagnosis of and treatment for advanced breast cancer will be prevented, which is apart from the life-years gained the second most important favourable effect of screening.
By including the gain in 440 Quality = Adjusted Life-Years (QALY's) due to prevented advanced disease, screening as a whole leads to a relatively minor overall impact on quality of life. Unfavourable effects of screening are responsible for a decrease in quality of life of 10%, due to the loss in quality of life during the screening examination ( + 85) and in (more) treatment and follow up (+ 570 services is another aspect. The decrease in systemic and palliative treatments results in a prevention of drug treatment and in a decrease in hospital admissions and in-patient days, primarily noticed by the physician in internal medicine. However, changes in palliative surgical procedures or radiotherapeutic sessions will be small, which is quite in contrast to the large and immediate changes in primary treatment as a result of the implementation of screening .
The consequences of a 3-yearly screening interval for women aged 50-65 (UK policy) if implemented in the Netherlands are presented in the right column. The smaller age range invited is responsible for a 28% lower number of breast cancer deaths prevented. Due to the fact that women will have less screens with a 3-year interval (given the same time period), the number of prevented treatments will be reduced by another 13%, resulting in a total of 405 (versus 655 in the other policy). But again, the impact of preventing advanced disease on the total effects and expenditures is clear: 275 quality = adjusted life-years are gained due to less advanced disease and even 44% of the annual cost of screening are offset.
For both policies in Table V , the estimated mortality reduction is based on the reduction achieved in Kopparberg/ Osterg6tland and Malm6, which implies a 33% reduction in the age group 50-70 for a 2-year and a 21% reduction in the age group 50-65 for a 3-year interval programme with 70% attendance rate. The recent update of screening trials indicates an approximately 25% reduction, if the HIP-trial (Health Insurance Plan of Greater New York) and the TEDBC (UK Trial of Early Detection of Breast Cancer) are included and the actual differences in screening interval or attendance rate are neglected (Wald et al., 1991) . We have considered the HIP-results to be too outdated for predicting the effect of present European programmes. In our estimate, we corrected the results of both Swedish randomised trials for the specific differences in age groups, screening interval, attendance rate, follow up period, and trial size. Considering the other point estimates on mortality reduction, the 'Swedish average' appears a realistic one .
Discussion
Average treatment A comparison with literature and some national data was made to check whether the selection of patient files had not resulted in a serious bias. One of the main prognostic discriminants is the site and number of metastases, which makes it difficult to compare (inter-) national data deriving from different hospitals. Nevertheless, median post-recurrence survival is mostly in the range of 18-24 months (Powles et al., 1980; Patel et al., 1986; Tomin & Donegan, 1987; Perez et al., 1990; Dixon et al., 1991) , which strongly resembles our data (20.3 mo). Almost 60% of the women in the three hospitals had received radiation treatment for advanced disease. Our national survey amongst radiotherapy departments indicated that approximately 1925 female patients had been radiated in 1988 for advanced breast cancer, which is also approximately 60% of the annual number of women that died from breast cancer. In general, these data support our findings from the file study.
Literature on the cost of treating women with advanced disease is scarce. In the Netherlands, de Waard had analysed 52 files of women treated in 1973-74 for primary breast cancer, who had developed metastases in the 10 years after (de Waard et al., 1986) . With tariffs based on the public health insurance scheme, which are lower than those for privately insured patients, the cost of treating metastases was calculated to be US 16,000 (total duration of disease unknown). The average number of in-patient days was 66 in that time period, which highly influenced the cost. The lower number of 45 in our study is certainly a reflection of the policy in the eighties of not admitting all women to hospital for chemotherapy anymore. Medicare data from the United States have shown that the cost of care for breast cancer patients delivered during the last 6 months of life are 15,137 US dollars (Baker et al., 1991) . Cost for continuing care in the months before is 483 US dollars per month, but this is not just attributable to cancer. A baseline estimate for all Medicare patients was 235 US dollars per month. Total breast cancer expenditure for women surviving 21 months can be calculated to be approximately 19,000 US dollars.
Cost of treatment will remain uncertain, as the most important part of the cost is related to the number of inpatient days. Our analysis on all national admissions to hospital shows fewer in-patient days (in the range of 35 to 40), which is more in line with the median number of days in our patient files, but one can not select as specifically to advanced breast cancer as one is able to do with actual patient files. The same applies to in-patient days in nursing homes, although the national data are very close to those in the file study (9.5 instead of 8.3 days). However, in general our cost analysis is a moderate estimate, as cost for anal- Group, 1992 ) is a good example. Criticism may also be expressed on the calculated savings due to mass screening, as women whose advanced breast cancer has been prevented will have a chance of getting other diseases and use other medical resources. Furthermore, our direct scaling method should in the future be adapted for measurements in patients. We have not used different utilities for different age groups. The relationship between age at time of disease and utility is not clear cut. Some studies do find a relationship, others do not. Furthermore, if changes are found, they may be in different directions for each dimension (Cassileth et al., 1984; Nerenz et al., 1986; de Haes et al., 1990) . Nevertheless, our study does provide insight in the changes to be expected, at present, due to nationwide, screening.
Whether our results will be applicable to other countries will depend on four important factors. The number of inpatient days and the percentage of women treated with radiation are the most influential two factors for total costs. There may be differences between countries on these points. For instance, terminally ill breast cancer patients in Finland appeared to have been treated significantly less by radiation (Holli et al., 1989) . Recording the total durations of hormonal treatment and chemotherapy will be important for quality of life. Finally, the fourth and most important factor is the breast cancer mortality reduction that can be expected in different countries when implementing nationwide screening, as this is implicitly related to the prevention of advanced disease and its treatment, the savings and the gain in quality of life.
In overview, the impact of breast cancer screening with respect to the prevention of advanced disease and its morbidity is evident. In the long term, high quality screening will result in an important benefit for the women involved and in a considerable reduction of the amount of effort and money being spent to treat women with advanced disease. As long as there is no treatment highly effective against advanced disease, breast cancer screening will play an important role.
